Literature DB >> 15582041

Vioxx, the implosion of Merck, and aftershocks at the FDA.

Richard Horton1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15582041     DOI: 10.1016/S0140-6736(04)17523-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  22 in total

1.  Lessons to be learned from the Vioxx debacle.

Authors:  George A Beller
Journal:  J Nucl Cardiol       Date:  2005 Jan-Feb       Impact factor: 5.952

2.  Drug safety and regulation.

Authors:  Patrick C Waller; Stephen J W Evans; Keith Beard
Journal:  BMJ       Date:  2005-07-02

3.  Balancing the cyclooxygenase portfolio.

Authors:  Paul W Armstrong
Journal:  CMAJ       Date:  2006-05-23       Impact factor: 8.262

4.  Knowledge creation about ADRs--turning the perspective from the rear mirror to the projector?

Authors:  Lise Aagaard; Birthe Soendergaard; Doris I Stenver; Ebba Holme Hansen
Journal:  Br J Clin Pharmacol       Date:  2007-10-24       Impact factor: 4.335

5.  Rofecoxib-Induced Deleterious Effects Escape Detection by Organismal Performance Assays.

Authors:  Shannon M Gaukler; James S Ruff; Linda C Morrison; Wayne Potts
Journal:  J Pharm Negat Results       Date:  2016-02-19

Review 6.  The advancement of translational medicine-from regional challenges to global solutions.

Authors:  Salvatore Albani; Berent Prakken
Journal:  Nat Med       Date:  2009-09       Impact factor: 53.440

7.  Ten lessons to be learned from the withdrawal of Vioxx (rofecoxib).

Authors:  Xavier Carné; Núria Cruz
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

Review 8.  Human-Derived Organ-on-a-Chip for Personalized Drug Development.

Authors:  Yasamin A Jodat; Min G Kang; Kiavash Kiaee; Gyeong J Kim; Angel F H Martinez; Aliza Rosenkranz; Hojae Bae; Su R Shin
Journal:  Curr Pharm Des       Date:  2018       Impact factor: 3.116

9.  A public health perspective on research ethics.

Authors:  D R Buchanan; F G Miller
Journal:  J Med Ethics       Date:  2006-12       Impact factor: 2.903

Review 10.  Pharmacovigilance: methods, recent developments and future perspectives.

Authors:  L Härmark; A C van Grootheest
Journal:  Eur J Clin Pharmacol       Date:  2008-06-04       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.